EU medical device regulation

Q&A: All you Need to Know About the New EU Medical Device Regulation (MDR)

Q&A: All you Need to Know About the New EU Medical Device Regulation (MDR)

EU medical device regulation

Until now, the rules for medical device manufacturers in Europe were laid out in the EU Medical Device Directive (93/42/EEC). In effect since 1993, this decades-old regulatory framework will be replaced by the EU’s Medical Device Regulation (MDR) (2017/745). The latter was published on May 2017 and will be coming into force on May 2020, after a transition period of 3 years. At the time of writing, this leaves manufacturers exactly a year to conform with the MDR.

Being a more inclusive yet more strict regulatory framework, the MDR can be considered a modern update of the existing medical device directive. This article is a brief summary in the form of a Q&A, about the key changes and most important points of the new EU medical device regulation.

Q&A: New EU Medical Device Regulation

What is MDR’s Scope Compared to the Previous Directive?

The MDR has an expanded scope to include devices that are not strictly intended for medical purposes. Such device examples are cosmetic implants and colored contact lenses.

What are the Major Quality Changes with MDR?

Firstly as is already the case with pharmaceuticals, the role of Qualified Person (QP) is introduced under the MDR. So a manufacturer defined Qualified Person will assume full responsibility for medical device compliance, under the MDR. Secondly, the MDR mandates the use of Unique Device Identification (UDI) mechanisms. These allow for fast tracking and tracing of every medical device anywhere in the supply chain, for both the authorities and manufacturers, ultimately aiding in more effective medical device products recalls. Lastly, the new EU medical device regulation will allow the Commission with the aid of expert panels, to define and publish Common Specifications. These will need to be taken into account by both Notified Bodies and medical device manufacturers.

What is the MDR’s Approach on Clinical Data?

One big change is that MDR requires more comprehensive clinical evidence for high risk medical devices, such as class III and implants. These need to cover any claims regarding both performance and safety of a medical device. Moreover, manufacturers will need to assess potential safety risks with clinical data acquired post market, after the medical devices have been marketed and are in widespread use.

Regarding classes IIa and IIb medical devices, clinical evaluation will need to be repeated according to the new EU medical device regulation. As a result, manufacturers may need to conduct a new clinical investigation, or take an equivalence approach and justify why their existing clinical investigation is adequate.

Will Existing Approved Medical Devices Be Affected?

Yes, as every currently approved medical device must be recertified, under the new MDR. Moreover, the MDR requires medical device manufacturers to harmonize their technical documentation according to the new regulation. Then by taking into account the application risk, invasiveness, and duration of contact, manufacturers are to assess whether it is necessary for them to reclassify their medical devices.

Read More

Medical Device Manufacturing Outsourcing

Outsourcing Medical Device Manufacturing – OEM Top Concerns

Outsourcing the production of your medical device manufacturing can be a big step for your organization. As an Original Equipment Manufacturer (OEM), putting your product in the hands of a Contract Manufacturer (CM) will free up significant time for your design and production teams, streamline the manufacturing process and even give you access to new world markets.

Read more...
Full-service Medical Device Contract Manufacturer

Advantages Of A Full Service Medical Device Contract Manufacturer

If you’re considering outsourcing your manufacturing process, it’s recommended to look for a partner who can offer end-to-end service. Or a full-service medical device contract manufacturer. Finding the right partner who can help refine your design before diving into production will save big on time and money.

Read more...
Workforce During the COVID-19 Lockdown

Return of the Workforce During the COVID-19 Lockdown in China

When the Chinese government allowed manufacturers to re-open in the wake of the COVID-19 lockdown, Quasar and other companies couldn’t simply flip a switch to restart production. One of the biggest challenges manufacturers faced was in finding ways to bring the workforce back to the plant. In Quasar’s case, the majority of our 1,400-person workforce was spread across many different regions of the country.

Read more...